immune-mediated inflammatory diseases (paediatric)
Rheumatology · 2024–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Treatment of immune-mediated inflammatory diseases (IMIDs) in paediatric patients (under 18 years of age). The submission requested an indication-agnostic… | Dec 2024 | Deferred | 6 individuals Australian Paediatric Rheumatology Group · Juvenile Arthritis Foundation · National Institute · Arthritis Foundation · Rheumatology Research Alliance |
Who spoke
Australian Paediatric Rheumatology Group · Juvenile Arthritis Foundation · National Institute · Arthritis Foundation · Rheumatology Research Alliance
What the PBS pays
$242M in government benefit over 2024–25, across 411,820 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| adalimumab | $241.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.